Detalhe da pesquisa
1.
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
N Engl J Med
; 390(4): 301-313, 2024 Jan 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-38084760
2.
Predictors of unsustained measurable residual disease negativity in patients with multiple myeloma.
Blood
; 143(7): 592-596, 2024 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38048557
3.
Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial.
Lancet Oncol
; 24(1): 64-76, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36528035
4.
Specific targeting of the KRAS mutational landscape in myeloma as a tool to unveil the elicited antitumor activity.
Blood
; 138(18): 1705-1720, 2021 11 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-34077955
5.
Lenalidomide-based triplet regimens in first relapsed multiple myeloma patients: real-world evidence from a propensity score matched analysis.
Haematologica
; 108(3): 833-842, 2023 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36200419
6.
COVID-19 does not impact on outcome of myeloma patients infected while undergoing autologous stem cell transplantation.
Hematol Oncol
; 41(3): 555-558, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-36786526
7.
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials.
Hematol Oncol
; 40(4): 704-715, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-35608183
8.
The role of clonal hematopoiesis as driver of therapy-related myeloid neoplasms after autologous stem cell transplantation.
Ann Hematol
; 101(6): 1227-1237, 2022 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-35380239
9.
Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial.
Lancet Oncol
; 22(12): 1705-1720, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34774221
10.
Clinical characteristics and risk factors for mortality in hematologic patients affected by COVID-19.
Cancer
; 126(23): 5069-5076, 2020 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32910456
11.
Transplant eligibility in elderly multiple myeloma patients: Prospective external validation of the international myeloma working group frailty score and comparison with clinical judgment and other comorbidity scores in unselected patients aged 65-75 years.
Am J Hematol
; 95(7): 759-765, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32242970
12.
Predictive role of sustained imaging MRD negativity assessed by diffusion-weighted whole-body MRI in multiple myeloma.
Am J Hematol
; 98(9): E230-E232, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37317959
13.
Bone Marrow Stroma and Vascular Contributions to Myeloma Bone Homing.
Curr Osteoporos Rep
; 15(5): 499-506, 2017 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-28889371
14.
Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical experience with 300 cases outside of controlled clinical trials.
Haematologica
; 106(1): 291-294, 2021 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32107338
15.
An open-label phase 2 study treating patients with first or second relapse of multiple myeloma with carfilzomib, pomalidomide, and dexamethasone (KPd): SELECT study.
Leuk Lymphoma
; 65(6): 833-842, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38497533
16.
A real-world retrospective-prospective analysis of efficacy and safety of combined ixazomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma: The northern Italy experience.
Cancer Med
; 13(7): e7071, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38558233
17.
Additional copies of 1q negatively impact the outcome of multiple myeloma patients and induce transcriptomic deregulation in malignant plasma cells.
Blood Cancer J
; 14(1): 94, 2024 Jun 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-38849344
18.
Prospective evaluation of minimal residual disease in the phase II FORTE trial: a head-to-head comparison between multiparameter flow cytometry and next-generation sequencing.
EClinicalMedicine
; 60: 102016, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-37396800
19.
Impact of minimal residual disease standardised assessment by FDG-PET/CT in transplant-eligible patients with newly diagnosed multiple myeloma enrolled in the imaging sub-study of the FORTE trial.
EClinicalMedicine
; 60: 102017, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-37396807
20.
Circulating endothelial cells and endothelial activation in essential thrombocythemia: results from CD146+ immunomagnetic enrichment--flow cytometry and soluble E-selectin detection.
Am J Hematol
; 87(3): 319-20, 2012 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-22190201